Loading patent…
AssigneeAmerican Diagnostica, Inc.
InventorsRobert S. Greenfield, Seong Soo A. An
Estimating the term…
The invention is directed in part to a purified form of stabilized activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The invention is further directed to a method of producing stabilized TAFIa. The invention is also directed to methods for therapeutic use of stabilized TAFIa such as in the treatment, prevention or management of diseases via an anti-coagulant effect. The invention is also directed to methods for therapeutic use of inhibitors of TAFIa such as in the treatment, prevention or management of diseases via a procoagulant effect. The invention is also directed to methods of diagnostic use of stabilized TAFIa such as a standard in a chromogenic or a fluorometric carboxypeptidase activity assay. The present invention is also directed to kits comprising stabilized TAFIa useful in measuring carboxypepetidase activity.
A method of preparing stabilized TAFIa, said method comprising proteolytic cleavage of TAFI with a protease that cleaves TAFI to TAFIa in a substantially calcium-free environment.
A method of treating or managing a thrombotic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an inhibitor of TAFIa, wherein said inhibitor is captopril, captopril-phe, pro-phe-argininic acid, pro-trp-argininic acid, pro-tyr-argininic acid, pro-phe, pro-trp, pro-tyr, pro-phe-gly-argininic acid or argininic acid.
A method of preventing a thrombotic disorder in a patient, said method comprising administering to said patient a prophylactically effective amount of an inhibitor of TAFIa, wherein said inhibitor is captopril, captopril-phe, pro-phe-argininic acid, pro-trp-argininic acid, pro-tyr-argininic acid, pro-phe, pro-trp, pro-tyr, pro-phe-gly-argininic acid or argininic acid.
A method of treating or managing a hemorrhagic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of purified, stabilized TAFIa.
A method of preventing a hemorrhagic disorder in a patient, said method comprising administering to said patient a prophylactically effective amount of purified, stabilized TAFIa.
A method of ameliorating side-effects in a patient associated with anti-coagulant therapy, said method comprising administering to said patient a therapeutically effective amount of purified, stabilized TAFIa.
A purified enzyme which is a stable TAFIa.
A kit comprising in containers purified, stabilized TAFIa, a developer, an activation reagent in a 15% DMSO, 200 mM Tris-HCl, pH 7.4 buffer and instructions for use of said kit.
A method of detecting TAFIa activity in a test sample comprising the use of a fluorescent assay and stabilized TAFIa as a standard.
Dependencies are inferred from the claim text.